Tests ribupatide injection in adults with obesity and knee osteoarthritis
Tests ribupatide injection against placebo in adults with obesity and knee osteoarthritis.
Plain-language title generated from the registry record
Registry title: A Trial of Ribupatide Injection in Participants With Obesity and Knee Osteoarthritis
Key facts
- Where
- Shanghai, ChinaSee the site
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with obesity and knee osteoarthritis to test Ribupatide Injection against a placebo.
- Age
- 18 years or older
- Sex
- Men and women can join.
- Disease stage
- Knee osteoarthritis diagnosed by American College of Rheumatology criteria, with a K-L grade of 2-3 on knee X-ray at screening.
- Earlier treatment
- Diet and exercise control for 3 months or more before screening, with body weight change of 5.0 kg (11 lb) or less in the 3 months before screening. No other drug or medical device trial in the 3 months before screening.
- Biomarker or test result
- BMI of 28.0 kg/m² or higher at screening.
Main reasons for not taking part
- Endocrine disease that may strongly affect body weight
- History of pancreatitis, or gallbladder disease
- Personal or family history of medullary thyroid carcinoma or MEN2
- Severe heart or brain blood vessel disease in the last 6 months
- Cancer in any organ within the last 5 years
Read by machine on 12 November 2026.
Where in China
- Shanghai Sixth People's HospitalShanghai, ChinaContact: Changqing Zhang (principal investigator)No longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Trial code
- NCT07709910
- Record updated
- 17 July 2026
- Original description
The study is being conducted to evaluate the efficacy and safety of Ribupatide Injection in participants with obesity and knee osteoarthritis, and to explore its improvement on knee joint structure.Read full original descriptionShow less
A Multicenter, Randomized, Double-blind, Placebo-parallel-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of Ribupatide Injection in Participants With Obesity and Knee Osteoarthritis
The study is being conducted to evaluate the efficacy and safety of Ribupatide Injection in participants with obesity and knee osteoarthritis, and to explore its improvement on knee joint structure.
Inclusion: -; 1、Voluntarily sign the informed consent form, agree to comply with the protocol requirements, and be willing and able to complete the study; 2、Aged ≥18 years on the date of signing the informed consent form, male or female; 3、BMI ≥28.0 kg/m² at screening; 4、Self-reported dietary and exercise control for 3 months or more prior to screening, and body weight change (difference between maximum and minimum body weight within 3 months) ≤5.0 kg in the 3 months prior to screening; 5、Based on the American College of Rheumatology criteria, the clinical diagnosis is knee osteoarthritis, and the target knee joint X-ray examination shows a K-L grade of 2-3 at screening.
Exclusion: Severe infection, major trauma, or major/medium surgery within 1 month prior to screening; History of severe cardiovascular or cerebrovascular diseases within 6 months prior to screening; Participation in any drug or medical device clinical trial within 3 months prior to screening; Blood donation or cumulative blood loss ≥400 mL within 3 months prior to screening, or receipt of blood transfusion within 3 months; Existence of endocrine diseases that may significantly affect body weight; Existence of any conditions affecting gastric emptying; Known history of acute or chronic pancreatitis, pancreatic injury, acute cholecystitis, or symptomatic/treated gallbladder diseases; Known history or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2); History of malignancy in any organ system within 5 years prior to screening; Existence or suspicion of depression, bipolar disorder, suicidal tendencies, schizophrenia, or other serious mental illnesses; Known or suspected history of alcohol and/or drug abuse or addiction; Symptoms or signs of acute or chronic hepatitis, or any liver disease other than metabolic dysfunction-associated fatty liver disease; Existence of serious hematologic diseases or any conditions causing hemolysis or red blood cell instability; Existence of autoimmune diseases requiring systemic glucocorticoid or immunosuppressive therapy during the study period; Known or suspected allergy to GLP-1 and/or GIP receptor agonists or their excipients; Participants with mental incompetence or language impairments that prevent full understanding or participation in the trial process.